Metro Healthcare Berhad, (0329) Fair Value & Analysis
Healthcare · MY · Market cap 215M MYR
Fair value as of: Jun 24, 2026
Analysis
Metro Healthcare Berhad, (0329) currently trades at 0.2150 MYR, while our model-based Fair Value estimate is 0.1400 MYR — implying the stock looks roughly 34.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Metro Healthcare Berhad, together with its subsidiaries, provides hospital and related services in Malaysia. It offers inpatient; outpatient; and ambulatory care, including in vitro fertilization (IVF), intrauterine insemination (IUI), blastocyst culture, surgical sperm retrieval, preimplantation genetic screening (PGT), and assisted hatching services. The company also provides fertility services, such as assisted reproductive technology and specialized fertility procedures; and obstetrics services that include pre-pregnancy screening and counselling, family planning counselling, antenatal checkup, and delivery services. In addition, it offers gynecology services, including hysterectomy, oophorectomy, colposcopy, hysteroscopy, laparoscopy, tubal ligation, dilation and curettage, and marsupialization; pediatrics services; diagnostic imaging services; and other healthcare services. Metro Healthcare Berhad was founded in 1989 and is based in Klang, Malaysia.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Metro Healthcare Berhad, (0329) undervalued?
What is the fair value of 0329?
What is the quality score of 0329?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.